Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Financing Activities (2016 - 2025)

Wave Life Sciences' Cash from Financing Activities history spans 11 years, with the latest figure at $439.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1156.95% year-over-year to $439.7 million; the TTM value through Dec 2025 reached $488.2 million, up 92.3%, while the annual FY2025 figure was $488.2 million, 92.3% up from the prior year.
  • Cash from Financing Activities reached $439.7 million in Q4 2025 per WVE's latest filing, up from $32.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $439.7 million in Q4 2025 to a low of $17000.0 in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $49.9 million, with a median of $10.2 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 177757.89% in 2021, then crashed 99.84% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $33.8 million in 2021, then plummeted by 99.84% to $55000.0 in 2022, then soared by 170740.0% to $94.0 million in 2023, then tumbled by 62.77% to $35.0 million in 2024, then surged by 1156.95% to $439.7 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Cash from Financing Activities are $439.7 million (Q4 2025), $32.7 million (Q3 2025), and $11.7 million (Q2 2025).